Quantbot Technologies LP Invests $1.35 Million in LeMaitre Vascular, Inc. $LMAT

Quantbot Technologies LP purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,095 shares of the medical instruments supplier’s stock, valued at approximately $1,353,000. Quantbot Technologies LP owned 0.06% of LeMaitre Vascular as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of LMAT. Sound Income Strategies LLC grew its position in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in LeMaitre Vascular during the 1st quarter worth about $32,000. Geneos Wealth Management Inc. boosted its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the period. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth about $47,000. Finally, Quarry LP grew its holdings in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 1.2%

Shares of LMAT opened at $78.97 on Wednesday. LeMaitre Vascular, Inc. has a 1 year low of $78.29 and a 1 year high of $118.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The stock has a 50 day simple moving average of $93.85 and a two-hundred day simple moving average of $99.56. The firm has a market cap of $1.81 billion, a P/E ratio of 27.71, a P/E/G ratio of 2.31 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The company’s revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $0.60 earnings per share. On average, analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be issued a $0.25 dividend. The ex-dividend date is Thursday, August 20th. This represents a $1.00 annualized dividend and a dividend yield of 1.3%. LeMaitre Vascular’s payout ratio is currently 35.09%.

Analyst Upgrades and Downgrades

LMAT has been the subject of several research analyst reports. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wells Fargo & Company dropped their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 5th. Finally, Citizens Jmp boosted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Hold” and an average target price of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.